118 related articles for article (PubMed ID: 20559979)
1. Approval of high-risk medical devices in the US: implications for clinical cardiology.
Rome BN; Kramer DB; Kesselheim AS
Curr Cardiol Rep; 2014; 16(6):489. PubMed ID: 24760423
[TBL] [Abstract][Full Text] [Related]
2. Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments.
Wild C; Erdös J; Zechmeister I
BMC Cardiovasc Disord; 2014 Nov; 14():154. PubMed ID: 25366498
[TBL] [Abstract][Full Text] [Related]
3. Advancing Regulatory Science With Computational Modeling for Medical Devices at the FDA's Office of Science and Engineering Laboratories.
Morrison TM; Pathmanathan P; Adwan M; Margerrison E
Front Med (Lausanne); 2018; 5():241. PubMed ID: 30356350
[TBL] [Abstract][Full Text] [Related]
4. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
Evans BJ
Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
[TBL] [Abstract][Full Text] [Related]
5. Data Requirement for Animal-Derived Wound Care Devices: Limitations of the 510(k) Regulatory Pathway.
DeLong MR; Wells MW; Chang IA; Vardanian AJ; Harris H
J Am Coll Surg; 2024 Feb; 238(2):218-224. PubMed ID: 37796150
[TBL] [Abstract][Full Text] [Related]
6. The medical device development ecosystem: Current regulatory state and challenges for future development: A review.
Holmes DR; Farb A; Dib N; Jacques L; Rowe S; DeMaria A; King S; Zuckerman B
Cardiovasc Revasc Med; 2024 Mar; 60():95-101. PubMed ID: 37778922
[TBL] [Abstract][Full Text] [Related]
7. More than algorithms: an analysis of safety events involving ML-enabled medical devices reported to the FDA.
Lyell D; Wang Y; Coiera E; Magrabi F
J Am Med Inform Assoc; 2023 Jun; 30(7):1227-1236. PubMed ID: 37071804
[TBL] [Abstract][Full Text] [Related]
8. The 510(k) Third Party Review Program: Promise and Potential.
Miller BJ; Blanks W; Yagi B
J Med Syst; 2023 Aug; 47(1):93. PubMed ID: 37642768
[TBL] [Abstract][Full Text] [Related]
9. Regulatory considerations for medical imaging AI/ML devices in the United States: concepts and challenges.
Petrick N; Chen W; Delfino JG; Gallas BD; Kang Y; Krainak D; Sahiner B; Samala RK
J Med Imaging (Bellingham); 2023 Sep; 10(5):051804. PubMed ID: 37361549
[TBL] [Abstract][Full Text] [Related]
10. Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing.
Yim SH; Chung YJ
Genomics Inform; 2014 Dec; 12(4):151-5. PubMed ID: 25705152
[TBL] [Abstract][Full Text] [Related]
11. Question-based development of high-risk medical devices: A proposal for a structured design and review process.
White NA; Oude Vrielink TJC; van der Bogt KEA; Cohen AF; Rotmans JI; Horeman T
Br J Clin Pharmacol; 2023 Jul; 89(7):2144-2159. PubMed ID: 36740771
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.
Meshinchi S; Hunger SP; Aplenc R; Adamson PC; Jessup JM
Clin Cancer Res; 2012 Mar; 18(6):1547-54. PubMed ID: 22422407
[TBL] [Abstract][Full Text] [Related]
13. Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway.
Aboy M; Crespo C; Stern A
NPJ Digit Med; 2024 Feb; 7(1):29. PubMed ID: 38332182
[TBL] [Abstract][Full Text] [Related]
14. The FDA Review Process for Cardiac Medical Devices in Children: A Review for the Clinician.
Almond CS
Prog Pediatr Cardiol; 2012 May; 33(2):105-109. PubMed ID: 22661882
[TBL] [Abstract][Full Text] [Related]
15. Medical device risk (re)classification: lessons from the FDA's 515 Program Initiative.
Mooghali M; Rathi VK; Kadakia KT; Ross JS; Dhruva SS
BMJ Surg Interv Health Technol; 2023; 5(1):e000186. PubMed ID: 38033980
[No Abstract] [Full Text] [Related]
16. Pediatric Medical Devices　- Survey of Pediatric Cardiologists and Cardiovascular Surgeons in Japan.
Miyoshi T; Kato A; Yasukochi S; Takahashi S; Ho M; Yamamoto H; Inuzuka R; Kim SH; Sakamoto K; Kobayashi T
Circ Rep; 2021 Jan; 3(3):153-160. PubMed ID: 33738348
[No Abstract] [Full Text] [Related]
17. Barriers to medical device innovation.
Bergsland J; Elle OJ; Fosse E
Med Devices (Auckl); 2014; 7():205-9. PubMed ID: 24966699
[TBL] [Abstract][Full Text] [Related]
18. FDA regulation of cardiovascular devices and opportunities for improvement.
Dhruva SS; Redberg RF
J Interv Card Electrophysiol; 2013 Mar; 36(2):99-105. PubMed ID: 23263896
[TBL] [Abstract][Full Text] [Related]
19. FDA's perspectives on cardiovascular devices.
Chen EA; Patel-Raman SM; O'Callaghan K; Hillebrenner MG
J Cardiovasc Transl Res; 2009 Jun; 2(2):143-6. PubMed ID: 20559979
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
